Involution-based biomarkers of breast cancer risk
Involution-based biomarkers of breast cancer risk
批准号:
9886777
负责人:
Amy C Degnim
金额:
$55.48万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-09-01 至 2025-05-31
关键词:
AbbreviationsAddressAffectAfrican AmericanAgeAgingBenignBiologicalBiological MarkersBiopsyBreastBreast Cancer PreventionBreast Cancer Risk FactorBreast DiseasesBreast Epithelial CellsBreast biopsyCaucasiansCellsClinicClinicalControl GroupsCytometryDataDevelopmentDiagnosisEpithelialEpithelial CellsEpitheliumEvaluationExperimental ModelsFutureGoalsHumanImmunohistochemistryIncidenceInvestigationKnowledgeLactationLinkLobularLobuleMalignant NeoplasmsMammary Gland ParenchymaMediator of activation proteinMenopauseMethodsModelingMolecularMyoepithelial cellPathway interactionsPatientsPerimenopausePhenotypePhysiologicalPhysiological ProcessesPopulationPopulation HeterogeneityPostmenopausePreventionProcessPublishingRaceResearchResearch DesignRiskRisk AssessmentRisk ManagementSignal PathwaySiteSourceStructureTestingTimeTissue SampleWNT Signaling PathwayWomanWorkXenograft Modelage relatedbasebenign statecancer riskcase controlchild bearingcohortexperimental studyhigh riskhuman diseasehumanized mouseimprovedinnovationinsightmalignant breast neoplasmmammary epitheliummilk productionmouse modelnano-stringnovelperiostinpredictive markersurveillance strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
The breast lobules are the structures that produce milk in lactating women, and are also the primary
site of origin for breast cancer. Age-related lobular involution (LI) is a physiological process in which the
epithelial tissue of the breast lobules gradually regresses with age, corresponding with elimination of the need
for milk production beyond the child-bearing years. Analysis of our cohort of more than 14,000 women with
benign breast disease (BBD) revealed that LI is strongly associated with reduced risk of subsequent breast
cancer, and thus LI constitutes a natural mechanism for prevention of breast cancer. However, more than 40%
of postmenopausal women with BBD have not completed LI, and these women are at substantially greater risk
of developing breast cancer compared to women of similar age whose involution process has completed. In
this application, we propose experiments to identify critical effectors of LI and to determine how these can be
used to improve breast cancer risk assessment for women who have not undergone LI. In Aim 1, we will define
the mediators that underlie the link between delayed LI and a high risk cellular phenotype. We will use a newly-
generated panel of very early passage primary human mammary epithelial cells (HMECs) derived from women
with BBD and varying degrees of LI, in combination with humanized mouse xenograft models in which the LI
status of the HMECs is manifest. In Aim 2, we will identify mediators associated with ongoing vs delayed LI in a
newly-defined clinical cohort of peri- and post-menopausal women for whom multiple, sequential benign
biopsies are available. In Aim 3, biomarkers discovered in Aims 1 and 2 (plus other promising biomarkers) will
be evaluated for association with subsequent breast cancer in a patient cohort of postmenopausal women.
The cohorts interrogated in Aims 2 and 3 will be drawn both from the Mayo Clinic BBD cohort, which is
primarily composed of White/Caucasian women, and the Detroit BBD cohort, which is composed of
Black/African-American women, which will allow us to evaluate race as a biological variable in our analyses. By
providing insight into the processes that control LI and by developing tractable experimental models in which to
evaluate the effects of modulating those processes, our work will provide a better understanding of LI delay
and its link to breast cancer and will point toward methods for inducing LI in women for whom this process is
stalled or delayed, as a physiologically-derived method for breast cancer prevention.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Involution-based biomarkers of breast cancer risk
-
批准号:10246253
-
项目类别:
-
资助金额:$50.75万
-
财政年份:2020
-
负责人:Amy C Degnim
-
依托单位:
Biomarkers to Improve Targeting of Breast Cancer Prevention in Women with Atypical Hyperplasia
-
批准号:10542756
-
项目类别:
-
资助金额:$89.07万
-
财政年份:2020
-
负责人:Amy C Degnim
-
依托单位:
Involution-based biomarkers of breast cancer risk
-
批准号:10627873
-
项目类别:
-
资助金额:$48.66万
-
财政年份:2020
-
负责人:Amy C Degnim
-
依托单位:
Biomarkers to Improve Targeting of Breast Cancer Prevention in Women with Atypical Hyperplasia
-
批准号:9884497
-
项目类别:
-
资助金额:$88.45万
-
财政年份:2020
-
负责人:Amy C Degnim
-
依托单位:
Involution-based biomarkers of breast cancer risk
-
批准号:10722154
-
项目类别:
-
资助金额:$14.87万
-
财政年份:2020
-
负责人:Amy C Degnim
-
依托单位:
Involution-based biomarkers of breast cancer risk
-
批准号:10406367
-
项目类别:
-
资助金额:$48.86万
-
财政年份:2020
-
负责人:Amy C Degnim
-
依托单位:
Predicting Breast Cancer Risk after Benign Percutaneous Biopsy
-
批准号:9900922
-
项目类别:
-
资助金额:$9.51万
-
财政年份:2019
-
负责人:Amy C Degnim
-
依托单位:
Predicting Breast Cancer Risk after Benign Percutaneous Biopsy
-
批准号:10411403
-
项目类别:
-
资助金额:$10.29万
-
财政年份:2018
-
负责人:Amy C Degnim
-
依托单位:
Predicting Breast Cancer Risk after Benign Percutaneous Biopsy
-
批准号:10194417
-
项目类别:
-
资助金额:$63.74万
-
财政年份:2018
-
负责人:Amy C Degnim
-
依托单位:
Predicting Breast Cancer Risk after Benign Percutaneous Biopsy
-
批准号:10430124
-
项目类别:
-
资助金额:$63.92万
-
财政年份:2018
-
负责人:Amy C Degnim
-
依托单位:
Molecular Discriminators in Benign Breast Tissue for Future Risk of ER positive a
-
批准号:8748158
-
项目类别:
-
资助金额:$54.16万
-
财政年份:2014
-
负责人:Amy C Degnim
-
依托单位:
Project 3
-
批准号:10708077
-
项目类别:
-
资助金额:$65.36万
-
财政年份:2005
-
负责人:Amy C Degnim
-
依托单位:
海外基金